ESPA new blood test could change the outlook for one of the deadliest cancers—pancreatic cancer—by catching it much earlier than ever before. Researchers identified two previously unknown proteins in the blood that, when combined with existing markers, dramatically improved detection accuracy. The four-marker test was able to spot pancreatic cancer in over 90% of cases and performed especially well even in early stages, when treatment has the best chance of success.
Pancreatic cancer has a poor prognosis, with only about 10% of patients living longer than five years after diagnosis. However, doctors believe survival could improve significantly if the disease is caught earlier, when treatment is more effective. Despite this, there are currently no reliable screening tools available to detect pancreatic cancer in its early stages.
Researchers supported by the National Institutes of Health (NIH) have created a new blood test designed to identify pancreatic ductal adenocarcinoma, one of the most lethal types of cancer. Because pancreatic cancer is often discovered only after it has advanced, treatment options are limited and survival rates remain low. This new approach, detailed in Clinical Cancer Research, could help detect the disease sooner and improve patient outcomes.
Know more: https://www.sciencedaily.com/releases/2026/03/260323005540.htm
